Ratings Neuronetics, Inc.

Equities

STIM

US64131A1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3.52 ^USD	-6.13%		-8.09%	+21.38%

Apr. 10	Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation	CI
Mar. 28	Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board	CI

Summary

The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
NEURONETICS, INC.	+21.38%	112M	C-
THERMO FISHER SCIENTIFIC	+7.71%	220B	B
DANAHER CORPORATION	+6.25%	185B	B-
INTUITIVE SURGICAL, INC.	+10.60%	133B	B-
BOSTON SCIENTIFIC CORPORATION	+26.73%	107B	A-
SIEMENS HEALTHINEERS AG	-0.57%	62.91B	A-
EDWARDS LIFESCIENCES CORPORATION	+15.42%	53.34B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.89%	47.71B	B+
AGILENT TECHNOLOGIES, INC.	-1.91%	40.29B	A
GE HEALTHCARE TECHNOLOGIES INC.	+11.16%	39.57B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes